Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + DOXIL vs DOXIL in Advanced Relapsed Ovarian Cancer
NCT00113607Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2005
- Primary completion
- Nov 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of trabectedin in ovarian cancer, sponsored by Johnson & Johnson. Started Apr 2005; status: completed.
02
Drugs
trabectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00113607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113607.